Multicentric validation of a Multimorbidity Adjusted Disability Score to stratify depression-related risks using temporal disease maps

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The initiative was supported by ERA PerMed program (TRAJECTOME project, ERAPERMED2019-108).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

As a multicentric study, TRAJECTOME accessed multiple cohorts data, all subject to the legal regulations of their respective regions of origin and obtained the necessary approvals from the corresponding ethics committees. For CHSS cohort, the Ethical Committee for Human Research at Hospital Clinic de Barcelona approved the core study of TRAJECTOME on the 24th of March of 2021 (HCB/2020/1051) and subsequently approved the analysis for the generation and validation of MADS on the 25th of July of 2022 (HCB/2022/0720). UK Biobank received ethical approval from the National Research Ethics Service Committee Northwest Haydock (ref. 11/NW/0382). The THL cohort integrates information from the Finrisk databases: 1997 (Ethical committee of National Public Health Institute. Statement 38/96. 30.10.1996), 2002 (Helsinki University Hospital, Ethical committee of epidemiology and public health, Statement 87/2001. Reference 558/E3/2001. 19.12.2001), 2007 (Helsinki University Hospital, Coordinating ethics committee, Dnro HUS 229/EO/2006, 20.6.2006) and 2012 (Helsinki University Hospital, Coordinating ethics committee, Dnro HUS 162/13/03/11, 1.12.2011), the FinHealth 2017 (Helsinki University Hospital, Coordinating ethics committee, 37/13/03/00/2016 22.3.2016) and the Health 2000/2011 databases (Ethical committee of National Public Health Institute, 8/99/12. Helsinki University Hospital, Ethical committee of epidemiology and public health, 407/E3/2000. 31.05.2000 and 17.06.2011). The ethics committees exempted the requirement to obtain informed consent for the analysis, and publication of retrospectively acquired and fully anonymized data in the context of this noninterventional study. All the data was handled in compliance with the General Data Protection Regulation 2016/679, which safeguards data protection and privacy for all individuals in the European Union. The study was conducted in conformity with the Helsinki Declaration (Stronghold Version, Brazil, October 2013) and in accordance with the protocol and the relevant legal requirements (Biomedical Research Act 14/2007 of 3 July).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes